Samuel Samnick
Overview
Explore the profile of Samuel Samnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dreher N, Dorrler A, Kraus S, Rasche L, Higuchi T, Samnick S, et al.
Clin Nucl Med
. 2025 Mar;
PMID: 40042800
Background: Markedly expressed on hematopoietic stem cells, C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) has been used in relapsed/refractory (r/r) MM to prepare for hematopoietic stem cell transplantation...
2.
von Hinten J, Kircher M, Dierks A, Pfob C, Higuchi T, Pomper M, et al.
Front Nucl Med
. 2024 Oct;
2:801792.
PMID: 39354963
Due to its proven value in imaging of multiple myeloma (MM), including staging, prognostication, and assessment of therapy response, 2-deoxy-2-[F]fluoro-D-glucose (FDG) positron emission tomography (PET) is utilized extensively in the...
3.
Werner R, Zhi Y, Dreher N, Samnick S, Kosmala A, Higuchi T, et al.
Mol Imaging Biol
. 2024 Aug;
26(5):774-779.
PMID: 39090381
Methods: 50 subjects with MZL underwent CXCR4-targeted PET/CT, which were reviewed by four readers (including two experienced and two less experienced observers). The following 8 parameters were investigated: overall scan...
4.
Fezeu F, Jbara O, Jbarah A, Choucha A, De Maria L, Ciaglia E, et al.
Clin Neurol Neurosurg
. 2024 Jun;
243:108404.
PMID: 38944021
Parkinson's disease (PD) is the second most prevalent neurodegenerative condition after Alzheimer's disease and it represents one of the fastest emerging neurological diseases worldwide. PD is usually diagnosed after the...
5.
Hahner S, Higuchi T, Serfling S, Samnick S, Fuss C, Heinze B, et al.
Clin Nucl Med
. 2024 Feb;
49(4):369-370.
PMID: 38350087
We report on an adrenocortical carcinoma (ACC) patient, which has exhausted previous treatment options and was scheduled for prostate-specific membrane antigen (PSMA)- and C-X-C motif chemokine receptor 4 (CXCR4)-targeted PET/CT....
6.
Israel I, Riehl G, Butt E, Buck A, Samnick S
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256878
Kisspeptins (KPs, KISS1) and their receptor (KISS1R) play a pivotal role as metastasis suppressor for many cancers. Low or lost KP expression is associated with higher tumor grade, increased metastatic...
7.
Dreher N, Hahner S, Fuss C, Schlotelburg W, Hartrampf P, Serfling S, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(5):1383-1394.
PMID: 38082196
Background: C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in various solid cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to characterize the in-vivo CXCR4 expression in...
8.
Dreher N, Dorrler A, Kraus S, Higuchi T, Serfling S, Samnick S, et al.
Clin Nucl Med
. 2023 Dec;
49(2):146-151.
PMID: 38081189
Background: After C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT), lymphoma patients are scheduled for conditioning therapy (CON) followed by hematopoietic stem cell transplantation (HSCT). We aimed to determine...
9.
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Duell J, Buck A, Hartrampf P, Schlotelburg W, Schneid S, Weich A, et al.
J Nucl Med
. 2023 Oct;
64(12):1889-1894.
PMID: 37797975
Because of gastral and extranodal manifestations, guideline-compatible diagnostic work-up of marginal zone lymphoma is challenging. We aimed to determine the diagnostic performance of C-X-C motif chemokine receptor 4 (CXCR4)-directed PET/CT...
10.
Buck A, Serfling S, Kraus S, Samnick S, Dreher N, Higuchi T, et al.
J Nucl Med
. 2023 Jun;
64(7):1009-1016.
PMID: 37290799
In the early 2000s, major clinical trials provided evidence of a favorable outcome from antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food and Drug Administration approval. For instance,...